.Nature Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after a mean consequence of 11 months, patients with metastatic intestinal cysts that obtained biomarker-matched treatments based on flowing cyst DNA profiling showed a better scientific benefit than those acquiring incomparable treatment.